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Primary Drug Resistance to Antituberculous drugs in NWFP Pakistan
Arshad Javaid1, Abdul Ghafoor2, Abdul Rab3, Anila Basit4, Zia ullah5, Shaukat Ali6, Afia Zafar7, Rumina Hasan8
Department of Pulmonology1,4,5, PGMI, Lady Reading Hospital Peshawar, TB Control Programme2,6, NWFP, Department of Pulmonology3,
Ayub Teaching Hospital Abbotabad, Department of Microbiology7,8, Agha Khan University Hospital Karachi.
Abstract
Objective: To assess the prevalence of Primary drug resistance to Antituberculous drugs in NWFP
Method: A cross-sectional prevalence study was undertaken to evaluate the prevalence of drug resistance
among new TB patients, using a non-probability convenience sampling methodology. Sample size was
calculated according to the population and WHO's estimated incidence of smear positive tuberculosis in the
province/country. Sputum samples were obtained from 122 newly diagnosed patients of pulmonary tuberculosis
from centres in Peshawar and Abbotabad in NWFP. 
Results: Sensitivities were performed by proportion method which showed the following resistance values in 118
eligible patients: 15 (12.7 %) samples showed primary resistance to one or more drugs.  8 (6.4%) isolates were
resistant to a single drug, 2 (1.6%) were resistant to 2 drugs, 4 (3.2%) to 3 drugs, 1 (0.8%) to 4 drugs while none
to all 5 first line agents. Resistance to Streptomycin (10µg/ml) was seen in 7 (5.9%), Isoniazid (1µg/ml) in 10
(8.4%), Rifampicin (5µg/ml) in 3 (2.5%), Ethambutol (10µg/ml) in 2 (1.6%) and Pyrazinamide in 6 (5,0%)
samples.  Primary Multidrug resistance was 2.5%. 
Conclusion: This study suggests that prevalence of MDR amongst untreated patients in NWFP is 2.5%, which
is a cause of concern and should be addressed through effective TB control programmes with DOTS strategy
(JPMA 58:437;2008).
Introduction
Tuberculosis is a serious public health problem in the
developing countries. Worldwide emergence of multidrug
resistance tuberculosis (MDRTB) has been reported in both
developed and the developing countries and poses a major
threat to the control of TB.1 Drug resistance is primary when
it develops in a person who has never received anti TB
treatment in the past. This is in contrast to acquired drug
resistance, which is present in previously treated patients
with inadequate or irregular chemotherapy. World Health
Organization-International Union against Tuberculosis and
Lung Disease from a global surveillance for
antituberculosis-drug resistance, reported the prevalence of
Primary MDR at 1.4% and 13% in previously treated
patients.2 A survey from 48 geographic sites revealed that
drug resistant tuberculosis is ubiquitous and median
prevalence of primary resistance to at least one drug in
around 10.7 % and that of Primary MDR only 1%.3
In Pakistan, the incidence of TB is estimated to be
181 per 1,00,000 population and each year at least 286,000
new TB cases are added to the existent patient population of
around 1.8million.4 In NWFP alone 36000 new cases develop
tuberculosis annually. The level of drug resistance is known
to provide an epidemiological indicator to assess the extent of
resistant bacterial transmission in the community as well as
success or otherwise of National Tuberculosis Programme
(NTP). High levels of resistance have been reported in certain
regions of the world particularly in Asia and parts of Africa.5-
11 The recommendation to use drug susceptibility tests for
monitoring and guiding tuberculosis treatment programme
was made many years ago.12 In view of the practical
difficulties in collecting comparable data, the World Health
Organization (WHO) proposed a programme of global
surveillance of drug resistance in Tuberculosis through its
collaborating centres for bacteriology of tuberculosis which
would function as supranational Reference Laboratories
(SRL) for the respective regions. The proposed programme
was based on random sampling of patients reporting to clinics
for tuberculosis treatment. Susceptibility testing was to be
performed by the reference laboratories based on a common
protocol including uniform laboratory methods. As a first
step, a regional survey was carried out in 10 Latin American
countries.13 The overall experience gained in Latin America
suggested that a sample survey of drug resistance with large
failure rates of more than 5% may indicate inadequate routine
treatment and high levels of initial resistance, which made
survey of drug resistance a priority.13
Several countries in Asia and Africa undertook
national surveys in accordance with the protocol. Countries
including Tanzania,14 South Africa15 and India16 established
systematic national surveillance programmes. 
In Pakistan no such national/ provincial level survey
has ever been carried out. In a country ranked 6th in the
world in terms of TB disease burden and with 45% of TB
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disease burden of EMRO region, a resistance surveillance
study is badly needed in order to determine the prevalence,
pattern and trends of anti TB drug resistance in the country.
The fact that DOTs strategy has not been implemented in the
country until recently and TB patients by and large have
been treated unsupervised, it was assumed that primary drug
resistance is likely to be high in Pakistan. This hypothesis
was supported by reports from different cities of Pakistan
pointing towards a high drug  resistance rate,  One study
showed resistance to Rifampicin ((R)) and Isoniazid (INH)
to 15% and 11% respectively17 and in another one resistance
to H 25%, R 15%, E 12% and S 12%.18
A study from NWFP way back in 1994 also showed
relatively high primary and acquired drug resistance.19 In
order to test this hypothesis a study was conducted on
patients from all over the province presenting to diagnostic
centre in the main cities of NWFP i.e Abbottabad and
Peshawar. The objective of this study was to assess the
prevalence of primary drug resistance in the province.
Methods
The study was approved by Research and Ethics
Committee of Postgraduate Medical Institute Peshawar
Pakistan.
The study was designed to determine resistance of
Mycobacterium tuberculosis isolates from sputum cultures
of newly diagnosed smear positive TB patients, of NWFP
Province presenting with features of TB to diagnostic centres
in Peshawar and Abbottabad. The Centres were located in
the two main cities of NWFP where patients from all over
the province report. These included TB control Programme
centres in Peshawar and Abbottabad, out patient departments
of Govt: Leady Reading Hospital Peshawar and Ayub
Teaching Hospital Abbottabad and private clinics of all the
investigators where patients from all over the province
present themselves or are referrals for consultation. In all a
total of 7 centres participated in the study. 
Subjects Sputum smear examination was performed
at the respective diagnostic centres where the patients
suspected to have TB were screened. The subjects fulfilling
inclusion criteria with smear positive specimens were
enrolled in the study and their sputum were sent to the
collection centre of the central laboratory for culture and
sensitivity testing. 
This study was basically a cross-sectional study,
evaluating the prevalence of drug resistance among TB
patients diagnosed for the first time, with no prior exposure
to TB drugs, using a non-probability convenience sampling
methodology. The sample size was calculated according to
the population and WHO's estimated incidence of smear
positive tuberculosis in the province/country. According to
these calculations, a sample size of at least 122 was needed
for the study which was collected over a period of 4 months.
A sputum specimen in the container provided by the central
laboratory along with a form was filled by the investigator at
the diagnostic centre, giving beside other details a
declaration by the investigator that he has confirmed that the
patient has never taken anti-TB drugs in the past. Patients
were given an information leaflet and informed consent was
taken from all patients.   
New Smear Positive Pulmonary T.B patients of any
sex and age, living in NWFP with no prior T.B medication
history were included. Sputum has collected for Culture
before initiation of treatment.
The Department of Microbiology laboratory at Aga
Khan University Hospital was used as the Central
Laboratory for culture and sensitivity testing.  Smears for
microscopy were screened using Auramine Rhodamine
staining. Positive slides were further confirmed by staining
with Kinyoun modification of Ziehl Neelson stain.
Mycobacterial cultures were performed on both
liquid as well as solid media.  Sediments were cultured at
37oC using Lowenstein Jensen (LJ) medium and MIGIT
(Becton Dickinson Diagnostic Instruments Systems). For LJ
slant 0.1 ml of concentrated specimen was inoculated and
incubated for 8 weeks. MGIT vials were inoculated with 0.5
ml of specimen and incubated at 37oC after supplementation
of medium with OADC and PANTA; containing Polymyxin
B, Amphotericin B, Nalidixic acid, Trimethoprim and
Azlocilin. Growth from the positive LJ slant, and MGIT
vials were first stained with Kinyoun and M. tuberculosis
was identified by BACTEC NAP TB differentiation test
(Becton Dickinson, USA).
Susceptibility testing was performed using standard
agar proportion method on enriched Middle brook 7H10
medium (BBL) at the following final drug concentrations;
rifampicin  5ug/ml, isoniazid 1ug/ml, streptomycin10ug/ml
and ethambutol10ug/ml.20,21 Disc elusion sensitivity plates
were prepared using paper sensitivity disc (BBL).
McFarland No. 1 standard suspension of isolate was made
from growth on LJ slant and diluted to 10-2 and 10-4
dilutions. The inoculated plates were incubated at 35oC and
examined for growth each week for 8 weeks. M.tuberculosis
was considered resistant to a given drug when growth =1%
above the antibiotic free control was observed in drug
containing area.  Pyrazinamide sensitivity was carried out
g/ml (BACTEC using the BACTEC 7H12 medium pH6.0 at
100 TM PZA test medium, Becton Dickinson USA) in
accordance with manufacturers instructions. MTB H37Rv
was used as control with each batch of susceptibility testing. 
Data was analyzed using SPSS version 10. The
results are presented in the form of tables and graphs.
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Results
A total of 122 samples were evaluated of which 119
(97%) were found to be culture positive. Among the culture
positive patients, 53 (44.5%) were males and 66 (55.4%)
females with M/F ratio 1:1.25.  The age range of 75 (63%)
patients was between 15-35 years, 33 (27%) were above 35
years of age while 11 (9%) were below the age of 15 years.    
On smear examination 11 (9%) out of 119 smear
positive specimens collected were found to be smear
negative.
Drug susceptibility results were conducted on 119.
One sample grew Mycobacterium other than Tuberculosis
(MOTT) and hence was excluded from further analysis. Out
of the remaining 118 patients, the isolates from 103 (87.3%)
patients were fully susceptible to all the 1st line drugs tested,
while 15 (12.7%) patients showed resistance to one or more
drugs. Resistance to Isoniazid alone or in combination with
other drugs was seen in 10 (8.4%) patients. Similarly
resistance to streptomycin, Rifampicin, Ethambutal and
Pyrazinamide was seen in 7 (5.9%), 3 (2.5%), 2 (1.6) and 6
(5.0) respectively. 
Resistance to 1 drug was seen in 8 (6.4%) patients, 2
drugs in 2 (1.6%) patients, 3 drugs in 4 (3.2%) patients, 4
drugs in 1 (0.8%) patient and no sample showed resistance
to all 5 drugs. Primary MDR was found in 3 (2.5%) patients
(Table). 
Discussion
The WHO/IUATLD Global Project on Anti-
tuberculosis Drug Resistance Surveillance recorded
considerable variation in the prevalence of drug resistance
among 35 countries in 5 continents. The median prevalence
of Primary drug resistance was 9.9% with range of 2% to
41%. Overall, the median prevalence of primary MDR-TB
was 1.4% ranging from 0 to 10%. Among the South East
Asian Region (SEAR) countries, the prevalence of primary
resistance is readily available only for Nepal and Thailand
since they participated in the WHO supported Global Project
on Anti- tuberculosis Drug Resistance Surveillance in 1994-
97. The median prevalence of acquired resistance to any drug
was recorded as 23.2% with range of 9.8% to 36.6 %. The
median prevalence of primary MDR-TB was 2.5 %
significantly higher than the global mean of 1.4%.22 However
such information for other (SEAR) countries, based on
standardized protocols and methods, is not available. 
Although drugs resistance tuberculosis has frequently
been encountered in Pakistan and its presence has been
known, there is no comprehensive report, mainly due to
limited facilities available, for culture and susceptibility tests
across the country. The present study on drug resistance in
Pakistan using internationally acceptable guidelines and a
standardized methodology gives reliable baseline
information.
This study reveals culture positively of 97.6% of all
the smear positive patients, confirming the quality of
reference laboratory at AKU which was also up to the
acceptable standard.
The level of drug resistance to Isoniazid, Rifampicin,
and MDR of 8.4%, 2.5%, and  2.5%, respectively in
previously untreated cases, as is evident from this study, is
not as high as one would have expected, keeping in view that
NWFP has recently reached the WHO target of 100% DOTS
coverage. These values are comparable with resistance
studies in different 3rd world countries.23-25 However the
result of this study is different from other surveys conducted
in Pakistan. According to a study by Khan JA, et al, the
primary resistance to Isoniazed and Rifampicin was found to
be 11% and 15% respectively.17 n another study resistance
was found to be even higher with H 25%, R 15%, E 12% and
S19%.26 This relatively high percentage of resistance to
individual drugs in the studies from Pakistan27 was perhaps
due to the faulty selection of patients and it appears that
Table.  Resistance pattern of mycobacterium TB (15 resistant
samples).
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efforts were not made to separate primary drug resistance
from initial or acquired resistance. In view of the above
mentioned studies, it was realized that there is a strong need
to evaluate the primary resistance to Anti-tuberculosis drugs
in a Pan Pakistan study.
There has perhaps been a gradual increase in primary
drug resistance over the years. This could be overcome by a
strong control programme with DOTS strategy which can
reduce the emergence of drug resistance in the community.
Since no newer drugs for tuberculosis are likely to become
available in the near future, the only options left for the
prevention of drugs resistance are effective case finding,
prompt and correct diagnosis and successful treatment of
patients. Apart from a strong control programme, continuous
surveillance of drug resistance will provide information
which will serve as a useful parameter in the evaluation of
control programmes.
Conclusion
A poorly functioning programme can create MDR-
TB much faster than it can be treated, even if unlimited
resources are available. There is no single prescription for
controlling MDR-TB but the various tools available should
be applied wisely. Adoption of DOTS to prevent the
generation of resistant strains and careful introduction of
second-line drugs to treat patients with MDR are the top
priorities for proper control/containment of MDR-TB.
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